Literature DB >> 2258340

Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease.

E Dournon1, C Mayaud, M Wolff, B Schlemmer, D Samuel, J P Sollet, P Levasseur-Rajagopalan.   

Abstract

Comparison of the activity of different antibiotic regimens in Legionnaire's disease has never been made because of the rarity of well documented cases of that disease. We have retrospectively compared severe cases of Legionnaires' disease treated with pefloxacin alone or in combination with erythromycin and/or rifampicin using computer-matched cases treated either with erythromycin or with erythromycin in combination with rifampicin. This study suggests that: (1) combined therapy including erythromycin, rifampicin and/or pefloxacin is superior to therapy with erythromycin alone; (2) combinations including pefloxacin may be the most active ones; and (3) pefloxacin alone may be as active as combination therapy. Although these results are in agreement with data obtained in cell and in animal models of legionella infection they need to be further confirmed by the study of larger number of patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2258340     DOI: 10.1093/jac/26.suppl_b.129

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Treatment of Legionnaires' disease.

Authors:  Guy W Amsden
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

4.  Fatal Legionella pneumophila pneumonia: treatment failure despite early sequential oral-parenteral amoxicillin-clavulanic acid therapy.

Authors:  P Hohl; U Buser; R Frei
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

5.  In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella.

Authors:  S J Martin; S L Pendland; C Chen; P Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: a Danish historical cohort study.

Authors:  Sanne Jespersen; Ole S Søgaard; Henrik C Schønheyder; Michael J Fine; Lars Ostergaard
Journal:  BMC Infect Dis       Date:  2010-05-21       Impact factor: 3.090

Review 8.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

9.  Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis.

Authors:  Annie S Jasper; Jackson S Musuuza; Jessica S Tischendorf; Vanessa W Stevens; Shantini D Gamage; Fauzia Osman; Nasia Safdar
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 20.999

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.